Have a feature idea you'd love to see implemented?
Let us know!
FBRX Forte Biosciences Inc
Price (delayed)
$20.59
Market cap
$30.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$16.29
Enterprise value
$13.74M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
Highlights
FBRX's EPS is up by 48% YoY and by 11% QoQ
The net income has contracted by 12% YoY but it has grown by 4.4% from the previous quarter
The equity has plunged by 77% YoY and by 45% from the previous quarter
FBRX's quick ratio has dropped by 69% year-on-year and by 29% since the previous quarter
Key stats
What are the main financial stats of FBRX
Market
Valuations
Earnings
Shares outstanding
1.46M
Market cap
$30.1M
Enterprise value
$13.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$34.2M
EBIT
-$34.2M
EBITDA
-$34.16M
Free cash flow
-$29.73M
Per share
Balance sheet
Liquidity
EPS
-$16.29
EPS diluted
-$16.29
Free cash flow per share
-$16.09
Book value per share
$6.41
Revenue per share
$0
TBVPS
$9.71
Total assets
$17.95M
Total liabilities
$8.58M
Debt
$0
Equity
$9.37M
Working capital
$9.09M
Debt to equity
0
Current ratio
2.06
Quick ratio
1.91
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-118.9%
Return on equity
-151.4%
Return on invested capital
N/A
Return on capital employed
-365.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FBRX stock price
How has the Forte Biosciences stock price performed over time
Intraday
4.52%
1 week
10.34%
1 month
23.44%
1 year
10.76%
YTD
0.24%
QTD
268.34%
Financial performance
How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.63M
Net income
-$34.2M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 15% YoY but it has grown by 4.3% from the previous quarter
The net income has contracted by 12% YoY but it has grown by 4.4% from the previous quarter
Growth
What is Forte Biosciences's growth rate over time
Valuation
What is Forte Biosciences stock price valuation
P/E
N/A
P/B
3.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS is up by 48% YoY and by 11% QoQ
The equity has plunged by 77% YoY and by 45% from the previous quarter
The price to book (P/B) is 23% lower than the 5-year quarterly average of 4.0
Efficiency
How efficient is Forte Biosciences business performance
FBRX's return on equity has dropped by 70% year-on-year and by 29% since the previous quarter
The company's return on assets has shrunk by 54% YoY and by 20% QoQ
Dividends
What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FBRX.
Financial health
How did Forte Biosciences financials performed over time
FBRX's total assets is 109% greater than its total liabilities
FBRX's quick ratio has dropped by 69% year-on-year and by 29% since the previous quarter
The current ratio has dropped by 67% year-on-year and by 27% since the previous quarter
Forte Biosciences's debt is 100% less than its equity
The equity has plunged by 77% YoY and by 45% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.